- Previous Close
7.15 - Open
7.10 - Bid 7.25 x --
- Ask 7.50 x --
- Day's Range
6.95 - 7.10 - 52 Week Range
5.40 - 15.00 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
446.852M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-3.43 - Earnings Date Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: 2X10.SG
View MorePerformance Overview: 2X10.SG
Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2X10.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2X10.SG
View MoreValuation Measures
Market Cap
469.04M
Enterprise Value
263.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.69%
Return on Equity (ttm)
-171.46%
Revenue (ttm)
9.03M
Net Income Avi to Common (ttm)
-177.42M
Diluted EPS (ttm)
-3.43
Balance Sheet and Cash Flow
Total Cash (mrq)
222.32M
Total Debt/Equity (mrq)
89.64%
Levered Free Cash Flow (ttm)
-89.3M